

MEDIA RELEASE**For immediate release****ACROMECH strengthens foothold in healthcare sector, secures two contracts with an aggregate value of S\$7.1 million from a repeat customer**

- **Further strengthens foothold in the healthcare sector**
- **Contract wins contribute to strong cumulative order book of approximately S\$47 million**

SINGAPORE, 18 April 2016 - ACROMECH Limited (“ACROMECH”, or the “Company” and together with its subsidiary, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biomedical, research and academia sectors today announce that it has won two contracts totalling S\$7.1 million from a customer in the healthcare sector, thereby strengthening its position in this sector.

The first contract relates to the refurbishment and enhancement of a restructured hospital’s existing operating theatres and is scheduled to commence in May 2016 and complete in October 2016. The second contract involves the revamping of an existing ward and the addition of two new isolation rooms at the restructured hospital and is scheduled to commence in May 2016 and complete in November 2016.

Including the order book as at 8 March 2016, as disclosed in the Company’s offer document dated 6 April 2016, its current order book stands at approximately S\$47 million.

ACROMECH’s Executive Chairman and Managing Director, Mr Lim Say Chin, said: “We are greatly encouraged by the two contract wins from the healthcare sector, particularly so because it was received from our repeat customer. This is a reflection of their confidence in us and in our established track record and good reputation, which we have built over the years”.

These contracts will contribute to the revenue of the Group, and is expected to have a positive impact on the earnings per share and net tangible asset per share of the Group, for the current financial year ending 30 September 2016.

None of the Directors has any interest, direct or indirect, in the above contracts, other than through their respective shareholdings in the Company. As far as the Directors are aware, none of the substantial shareholders of the Company has any interest, direct or indirect, in the above contracts.

The prospects for Singapore's healthcare, biomedical, research and academia sectors remain bright, driven by the Government's plans on infrastructure spending in the healthcare sector as well as initiatives to grow the biomedical, research and academia sectors. ACROMEC seeks to ride on this growth momentum as evidenced by our strong order book.

-- End --

About ACROMECC Limited (SGX Stock Code: 1CH1)

ACROMECC is an established specialist engineering services provider with 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMECC's business is divided into two main business segments: (i) Engineering, procurement and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.

The Group mainly serves the healthcare, biomedical, research and academia, and electronics sectors. Acromec counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies. For more information, please visit www.acromec.com.

Media and Analysts Contact:

Mr Jerry Tan

Chief Financial Officer

Tel: +65 6415 0574

Email: jerry.tan@acromec.com

This media release has been prepared by ACROMECC and its contents have been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this media release.

This media release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms. Tan Pei Woon (Telephone: +65 6532 3829) at 1 Robinson Road #21-02 AIA Tower, Singapore 048542.